Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Tomokatsu Miyaki"'
Autor:
Takanori Suzuki, Kentaro Matsuura, Yuta Suzuki, Fumihiro Okumura, Yoshihito Nagura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Atsunori Kusakabe, Satoshi Narahara, Takayuki Tokunaga, Katsuya Nagaoka, Keita Kuroyanagi, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background & Aims Relationships of serum C‐C motif chemokine ligand 5 (CCL5) and C‐X‐C motif chemokine ligand 10 (CXCL10) levels with hot immune features have been reported in patients with hepatocellular carcinoma (HCC). Therefore, we
Externí odkaz:
https://doaj.org/article/62de0767db2a49edbc37c059b963d6d0
Autor:
Sayuki Iijima, Kentaro Matsuura, Tsunamasa Watanabe, Koji Onomoto, Takashi Fujita, Kyoko Ito, Etsuko Iio, Tomokatsu Miyaki, Kei Fujiwara, Noboru Shinkai, Atsunori Kusakabe, Mio Endo, Shunsuke Nojiri, Takashi Joh, Yasuhito Tanaka
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0118000 (2015)
The levels of expression of interferon-stimulated genes (ISGs) in liver are associated with response to treatment with pegylated interferon (PEG-IFN) plus ribavirin (RBV). However, associations between the responses of ISGs to IFN-based therapy and t
Externí odkaz:
https://doaj.org/article/d8197d49c70847a282720b72e5cb697f
Autor:
Yuki Tahata, Hayato Hikita, Satoshi Mochida, Nobuyuki Enomoto, Norifumi Kawada, Masayuki Kurosaki, Akio Ido, Daiki Miki, Hitoshi Yoshiji, Yasuhiro Takikawa, Ryotaro Sakamori, Yoichi Hiasa, Kazuhiko Nakao, Naoya Kato, Yoshiyuki Ueno, Hiroshi Yatsuhashi, Yoshito Itoh, Ryosuke Tateishi, Goki Suda, Taro Takami, Yasunari Nakamoto, Yasuhiro Asahina, Kentaro Matsuura, Taro Yamashita, Tatsuya Kanto, Norio Akuta, Shuji Terai, Masahito Shimizu, Satoshi Sobue, Tomokatsu Miyaki, Akihiro Moriuchi, Ryoko Yamada, Takahiro Kodama, Tomohide Tatsumi, Tomomi Yamada, Tetsuo Takehara
Publikováno v:
Journal of Gastroenterology. 57:120-132
Direct-acting antiviral (DAA) therapy enables a high rate of sustained virologic response (SVR) in patients with hepatitis C virus associated cirrhosis. However, the impact of DAA therapy on liver-related events in patients with cirrhosis is unclear.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24cf3335cff0c2868f28bfc325b09f8c
https://doi.org/10.1007/s00535-021-01845-5
https://doi.org/10.1007/s00535-021-01845-5
Autor:
Takanori Suzuki, Kentaro Matsuura, Kenji Urakabe, Fumihiro Okumura, Hayato Kawamura, Satoshi Sobue, Sho Matoya, Tomokatsu Miyaki, Yoshihide Kimura, Daisuke Kato, Atsunori Kusakabe, Yoshito Tanaka, Atsushi Ozasa, Yoshihito Nagura, Kei Fujiwara, Shunsuke Nojiri, Shinya Hagiwara, Shigeru Kusumoto, Takako Inoue, Yasuhito Tanaka, Hiromi Kataoka
Publikováno v:
Hepatology research : the official journal of the Japan Society of HepatologyREFERENCES.
We retrospectively investigated patients with administration of nucleos(t)ide analogs (NAs) for prevention of or against hepatitis B virus (HBV) reactivation, and their clinical outcomes after cessation of the NA.We enrolled 180 patients who were pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463c4fed6c90543c9769105b31d4257a
https://pubmed.ncbi.nlm.nih.gov/36461885
https://pubmed.ncbi.nlm.nih.gov/36461885
Autor:
Shozo Togawa, Yusuke Inoue, Takahito Katano, Tsutomu Mizoshita, Tomoya Sugiyama, Yoshihide Kimura, Tomokatsu Miyaki, Erina Suzuki, Yuka Marutani, Yoshikazu Hirata, Tomonori Yamada, Makoto Sasaki, Hiromi Kataoka
Publikováno v:
Indian Journal of Gastroenterology. 39:565-575
Switching tumor necrosis factor-α inhibitors is an important treatment option for refractory ulcerative colitis (UC) patients who fail the first anti-tumor necrosis factor-α therapy, although many questions about this option remain unanswered. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f66104234e613338d35f99306719e1
https://doi.org/10.1007/s12664-020-01092-1
https://doi.org/10.1007/s12664-020-01092-1
Autor:
Satoshi Tanida, Tsutomu Mizoshita, Taketo Suzuki, Hiromi Kataoka, Makoto Sasaki, Naomi Sugimura, Tomokatsu Miyaki, Shozo Togawa, Tomoya Sugiyama
Publikováno v:
Digestive and Liver Disease. 51:967-971
Background Anti-tumor necrosis factor-α agents are important for managing refractory intestinal Behcet’s disease. Few studies have reported the efficacy of anti-tumor necrosis factor-α monoclonal antibodies for intestinal Behcet’s disease due t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a8dacc87f8f246d1ead93fce5701c0c
https://doi.org/10.1016/j.dld.2018.10.024
https://doi.org/10.1016/j.dld.2018.10.024
Autor:
Kentaro Matsuura, Noboru Hirashima, Etsuko Iio, Takeshi Matsui, Tomokatsu Miyaki, Hiroshi Abe, Yuichiro Eguchi, Susumu Tsutsumi, Katsuhiko Iwakiri, Tomonori Senoh, Norio Itokawa, Jong-Hon Kang, Noritomo Shimada, Koichi Takaguchi, Masanori Atsukawa, Kayoko Matsunami, Kai Yoshizawa, Keizo Kato, Atsunori Kusakabe, Kei Fujiwara, Yasuhito Tanaka, Hideyuki Nomura
Publikováno v:
Journal of Gastroenterology. 54:339-346
The aim of this study is to ascertain whether the TLL1 variant at rs17047200 is associated with the development of HCC after achieving sustained virological response (SVR) by interferon (IFN)-free therapy for chronic hepatitis C (CHC). A total of 102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121c023dc9d40992981e2193e82b7d9f
https://doi.org/10.1007/s00535-018-1526-3
https://doi.org/10.1007/s00535-018-1526-3
Autor:
Yuichiro Eguchi, Tomonori Senoh, Atsunori Kusakabe, Tomokatsu Miyaki, Koichi Takaguchi, Masanori Atsukawa, Etsuko Iio, Noboru Shinkai, Shunsuke Nojiri, Hiroshi Abe, Kayoko Matsunami, Keizo Kato, Akihito Tsubota, Yasuhito Tanaka, Kei Fujiwara, Kentaro Matsuura, Noritomo Shimada
Publikováno v:
Hepatology Research. 47:1308-1316
Aim This study explored treatment outcomes of sofosbuvir (SOF)/ledipasvir (LDV) therapy for chronic hepatitis C patients with and without prior daclatasvir (DCV)/asunaprevir (ASV) therapy. Methods Overall, 530 Japanese patients who were infected with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06fce796fd0a548c4cd45d2ca212d4af
https://doi.org/10.1111/hepr.12898
https://doi.org/10.1111/hepr.12898
Autor:
Kai Yoshizawa, Yasuhito Tanaka, Noboru Hirashima, Etsuko Iio, Noritomo Shimada, Tomoyuki Kuramitsu, Yuichiro Eguchi, Takeshi Matsui, Hideyuki Nomura, Jong-Hon Kang, Noboru Shinkai, Tomokatsu Miyaki, Akihito Tsubota, Izumi Hasegawa, Shunsuke Nojiri, Koichi Takaguchi, Masanori Atsukawa, Kei Fujiwara, Hiroshi Abe, Atsunori Kusakabe
Publikováno v:
Journal of Gastroenterology. 52:94-103
The present study explored the treatment outcome of daclatasvir (DCV) and asunaprevir (ASV) therapy combining oral direct-acting antiviral agents (DAAs) for chronic hepatitis C (HCV) including liver cirrhosis according to resistance-associated varian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe4b415fbd7945f59311921b0b344ae1
https://doi.org/10.1007/s00535-016-1225-x
https://doi.org/10.1007/s00535-016-1225-x
Autor:
Takashi Joh, Makoto Ooyama, Yoshihito Nagura, Itaru Naitoh, Kazuki Hayashi, Kazutoshi Fujioka, Makoto Nakamura, Naruomi Jinno, Tomokatsu Miyaki, Yusuke Mizuno, Junko Momose
Publikováno v:
Internal Medicine
We report the case of a 71-year-old man with afferent loop obstruction (ALO) after Roux-en-Y reconstruction due to gastric cancer. Computed tomography showed a distended afferent loop and a dilatated bile duct. We could not reach the stricture site i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174854263e3c156d472ed661f0299627
https://pubmed.ncbi.nlm.nih.gov/29093418
https://pubmed.ncbi.nlm.nih.gov/29093418